ESKLEROSI ANITZA
![Foto de ESKLEROSI ANITZA](/img/grupo.png)
![Foto de University of California, San Francisco](/img/noimage_org.png)
University of California, San Francisco
San Francisco, Estados UnidosUniversity of California, San Francisco-ko ikertzaileekin lankidetzan egindako argitalpenak (8)
2024
-
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Journal of Extracellular Vesicles, Vol. 13, Núm. 2
2014
-
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
Multiple Sclerosis Journal, Vol. 20, Núm. 14, pp. 1851-1859
2013
-
Fine Mapping and Functional Analysis of the Multiple Sclerosis Risk Gene CD6
PLoS ONE, Vol. 8, Núm. 4
-
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
PLoS ONE, Vol. 8, Núm. 7
2011
-
Switching multiple sclerosis patients with breakthrough disease to second-line therapy
PLoS ONE, Vol. 6, Núm. 2
2009
-
Differential micro RNA expression in PBMC from multiple sclerosis patients
PLoS ONE, Vol. 4, Núm. 7
2008
-
Vanishing MS T2-bright lesions before puberty: A distinct MRI phenotype?
Neurology, Vol. 71, Núm. 14, pp. 1090-1093
2007
-
Increased transcriptional activity of milk-related genes following the active phase of experimental autoimmune encephalomyelitis and multiple sclerosis
Journal of Immunology, Vol. 179, Núm. 6, pp. 4074-4082